|
Madura, acquired for 170,000 guineas in November 2006, and sold 12 months later for 710,000 guineas 
Leto's half sister, Light Shift, wins the 2007 Epsom Oaks. Breeding Capital sold a 50% interest in Leto for 450,000 guineas in December 2007. Leto was purchased for 250,000 12 months earlier - photo by racingfotos.com 
Overdose, a close relation to Musicanna, wins a the Group 2 Sprint at Baden Baden. Overdose is now unbeaten in ten starts, including a Listed race, a Group Two and a Group Three - September 2008 - photo by racingfotos.com BREEDING CAPITAL PLCCrows Farm T 0845 003 1385 Welcome to the Breeding Capital WebsiteAn investment in Breeding Capital enables private individuals to access a portfolio of quality bloodstock assets. The Companies have the benefit of an experienced management team with a proven track record in managing high quality bloodstock assets. Breeding Capital is committed to maintaining a significant investor relations programme, and providing Shareholders with a clear exit strategy. The principal objective is to deliver returns to investors in the medium term. The global bloodstock industry is significant and the asset backing and liquidity of the underlying assets makes it an alternative asset class worthy of consideration. Breeding Capital has four different companies. Breeding Capital PLC raised £3.2 million in 2006, and is closed for further investment. Breeding Capital II PLC, Breeding Capital III PLC, and Breeding Capital IV PLC together raised £5 million in 2008. They are all closed too, having been oversubscribed. It is the intention to raise further funds in early 2010. If you are interested in Breeding Capital, please do not hesistate to contact us ManagementBreeding Capital has put in place a Board and management team with the necessary skills to deliver the Company's objectives. Christopher Holdsworth Hunt and William Sporborg collectively have over 35 years of experience in working with high growth companies; Simon Marsh, Charlie Gordon - Watson and Michael Youngs have worked together for thirteen years and have demonstrated an excellent track record in the bloodstock world. Portfolio of bloodstock assetsBreeding Capital is acquiring a portfolio of bloodstock assets, comprising high quality young broodmares, foals and yearlings available for resale, and other related bloodstock assets, such as stallion shares. The broodmares will be covered every year, with their offspring being sold at public auction, usually as yearlings. Tax AdvantagesThe Companies have received advance assurances from HM Revenue & Customs that the Offer Shares will rank as "eligible shares" for the purposes of the Enterprise Investment Scheme, with its attendant tax benefits. A 40% tax payer has 52% of his investment protected, as well as attractive upside tax treatment. For further details, please click here. Clear Exit StrategyBreeding Capital PLC will seek a liquidity event in 2010, either through a listing, a sale or by way of a return of cash to Shareholders. Breeding Capital II, Breeding Capital III and Breeding Capital IV will seek a liquidity event in 2012. Excellent Investor RelationsBreeding Capital keeps investors fully informed of developments which may have an impact on the portfolio. Details of mares acquired, foals born and yearlings sold are communicated via a website and regular email. Sibling performance both on the track and at stud are monitored and communicated. |